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A B S T R A C T   
Glutaric acidemia type 1 (GA1) is a disorder of cerebral organic acid metabolism resulting from biallelic mu-
tations of GCDH. Without treatment, GA1 causes striatal degeneration in > 80% of affected children before two 
years of age. We analyzed clinical, biochemical, and developmental outcomes for 168 genotypically diverse GA1 
patients managed at a single center over 31 years, here separated into three treatment cohorts: children in 
Cohort I (n = 60; DOB 2006–2019) were identified by newborn screening (NBS) and treated prospectively using 
a standardized protocol that included a lysine-free, arginine-enriched metabolic formula, enteral L-carnitine 
(100 mg/kg•day), and emergency intravenous (IV) infusions of dextrose, saline, and L-carnitine during illnesses; 
children in Cohort II (n = 57; DOB 1989–2018) were identified by NBS and treated with natural protein re-
striction (1.0–1.3 g/kg•day) and emergency IV infusions; children in Cohort III (n = 51; DOB 1973–2016) did 
not receive NBS or special diet. The incidence of striatal degeneration in Cohorts I, II, and III was 7%, 47%, and 
90%, respectively (p  <  .0001). No neurologic injuries occurred after 19 months of age. Among uninjured 
children followed prospectively from birth (Cohort I), measures of growth, nutritional sufficiency, motor de-
velopment, and cognitive function were normal. Adherence to metabolic formula and L-carnitine supple-
mentation in Cohort I declined to 12% and 32%, respectively, by age 7 years. Cessation of strict dietary therapy 
altered plasma amino acid and carnitine concentrations but resulted in no serious adverse outcomes. In con-
clusion, neonatal diagnosis of GA1 coupled to management with lysine-free, arginine-enriched metabolic for-
mula and emergency IV infusions during the first two years of life is safe and effective, preventing more than 
90% of striatal injuries while supporting normal growth and psychomotor development. The need for dietary 
interventions and emergency IV therapies beyond early childhood is uncertain.   
1. Introduction 
Glutaric acidemia type 1 (GA1; OMIM #231670) is a disorder of 
cerebral organic acid metabolism caused by biallelic variants of GCDH, 
which encodes a mitochondrial flavin-dependent glutaryl-CoA dehy-
drogenase (GCDH) that mediates degradation of lysine and tryptophan 
(Fig. 1). Neuronal GCDH deficiency results in proximal accumulation of 
glutaryl-coenzyme A (CoA) and its dicarboxylic acid derivatives, glu-
taric acid (GA) and 3-hydroxyglutaric acid (3HGA). These metabolites 
become concentrated in the brain due to its limited capacity to form 
5‑carbon carnitine and glycine conjugates from glutaryl-CoA [1,2] or 
export medium-chain dicarboxylates [3,4]. 
GCDH deficiency causes sudden degeneration of striatal neurons in 
at least 80% of untreated patients [5–8]. More than 90% of these 
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encephalopathic crises strike during an infectious illness within the first 
24 months of life but rarely occur without apparent provocation and 
may even happen in utero [9,10]. Regardless of their timing or me-
chanism, striatal lesions result in a complex extrapyramidal movement 
disorder that is the principal determinant of outcome. The predominant 
motor pattern observed is severe, generalized dystonia, which often 
abrogates speech, ambulation, and self-efficacy and results in co-
morbidities such as dysphagia, gastroesophageal reflux, joint disloca-
tion, scoliosis, pulmonary aspiration, and chronic pain. Intellect typi-
cally remains intact despite profound functional impairment. 
The birth incidence of GA1 is ~1 per 90,000 worldwide [11] but 
much higher among certain endogamous groups such as the Old Order 
Amish [12], a modern religious sect descended from a few hundred 
Swiss Anabaptists who immigrated to North America during the 
eighteenth century [13]. A population bottleneck followed by genera-
tions of genetic drift allowed a pathogenic GCDH c.1262C  >  T 
(p.Ala421Val) founder allele to reach carrier frequencies as high as 10% 
(birth incidence ~1 per 400) within certain extant Amish demes, and 
this apparently heritable form of ‘cerebral palsy’ was recognized within 
such communities long before it was linked to GCDH [14]. 
The Clinic for Special Children (CSC) is sited in rural Pennsylvania 
amid a large Amish population, and since 1989 has drawn an ethnically 
and genetically diverse group of 168 GA1 patients from 26 U.S. states 
and 6 countries. Here, we reflect upon this rich clinical experience to 
summarize historical trends in GA1 treatment, with special emphasis on 
the evolution of pathophysiological models and treatment strategies. 
Our data indicate that newborn screening (NBS) for GA1, when coupled 
to an appropriate metabolic formula and timely intravenous (IV) infu-
sion therapy during the first two years of life, prevents more than 90% 
of striatal injuries while supporting normal growth and psychomotor 
development. 
2. Patients and methods 
2.1. Cohorts 
The Institutional Review Board of Penn Medicine-Lancaster General 
Hospital approved the research protocol (2008–095-CSC) and parents 
consented in writing on behalf of their children. We studied a group of 
168 individuals born with GA1 between August 1973 and October 2019 
(current median age 11.8 years, range 0.2–43.6 years; 52% female), 
comprising 2276 patient-years of follow up and representing at least 41 
different pathogenic GCDH allele combinations (Table S1). Ninety-one 
(54%) patients were homozygous for the c.1262C  >  T (p.Ala421Val) 
variant, 46 (27%) were homozygous or compound heterozygous for 
other GCDH alleles, and 31 (18%) had no molecular testing but a 
compelling clinical and biochemical GA1 phenotype, including elevated 
C5DC concentrations in plasma, elevations of both C5DC and 3HGA in 
urine, congenital or infantile-onset macrocephaly, and characteristic 
middle cranial fossa fluid collections detected by magnetic resonance 
imaging [6,15]. 
For comparative analyses, we established three separate cohorts 
based on timing of diagnosis and method of treatment (Table 1): 
Cohort I 60 individuals (DOB 2006–2019) with GA1 were asymp-
tomatic when identified between 0 and 14 days of age by one of two 
NBS methods (quantification of glutarylcarnitine [C5DC] from dried 
filter blood spots or detection of GCDH c.1262C  >  T from umbilical 
cord blood). After confirmatory biochemical and molecular testing, 
each child in Cohort I was treated consistently from birth to present (for 
patients < 2 years) or until ≥2 years of age using a standardized pro-
tocol that included a lysine-free, arginine-enriched (Lys−Arg+) meta-
bolic formula (Glutarade, Nutricia North America), enteral L-carnitine 
(100 mg/kg•day), and emergency IV infusion of dextrose, saline, and L- 
carnitine (400 mg/kg•day) during illnesses (Table 2). 
Cohort II: 57 individuals (DOB 1989–2018) were identified by NBS 
and subsequently treated with emergency IV infusions during illness 
and a diet restricted to 1.0–1.3 g/kg•day of intact (i.e., ‘natural’) pro-
tein, but did not receive a lysine-free metabolic formula. 
Cohort III: 51 individuals (DOB 1973–2016) were diagnosed with 
GA1 either during a workup for motor disability (90%) or incidentally 
through cascade testing; they did not have NBS or receive preventative 
therapies. 
Data for Cohort I were collected prospectively to extend findings of 
a study initiated in 2006 to evaluate the safety and efficacy of a novel 
Lys−Arg+ metabolic formula [16]. For Cohorts II and III, we conducted 
retrospective chart reviews to gather data about the method and timing 
of diagnosis, treatment strategy, neurologic outcome, and medical co-
morbidities. 
2.2. Prospective treatment and monitoring protocol, cohort I (DOB 
2006–2019) 
2.2.1. Dietary therapy 
Children in Cohort I (n = 60) were prescribed approximately equal 
quantities of intact protein (1.0–1.3 g/kg•day) and modified Lys−Arg+ 
protein equivalent (1.0–1.3 g/kg•day) from birth to their present age 
(for those < 2 years) or at least two years of age (Table 2). The protein 
equivalent of Lys−Arg+ metabolic formula was devoid of L-lysine, re-
duced in L-tryptophan (0.6%), and enriched with L-arginine (10.8%) as 
compared to protein in human milk (6.9% lysine, 1.8% tryptophan, 
3.0% arginine) or commercial milk-based infant formulas (~9.1% ly-
sine, 1.8% tryptophan, 3.0% arginine). The Lys−Arg+ metabolic for-
mula otherwise contained fat, carbohydrate, micronutrients, and all 
Fig. 1. Pathophysiology of Glutaric Acidemia Type 1. The brain imports lysine 
and arginine via a common facilitative transporter (SLC7A1) at the blood-brain 
barrier (BBB). Lysine and arginine have similar Km values for SLC7A1 and 
compete for cerebral uptake within physiological concentrations ranges. The 
central nervous system (CNS) has a minimum lysine requirement for normal 
protein accretion and growth; lysine in excess of this requirement is normally 
oxidized via a GCDH-dependent degradation pathway. In GA1, the CNS pro-
duces glutaryl-CoA and its derivative dicarboxylic acids (glutarate and 3-hy-
droxyglutarate) in proportion to its rate of lysine uptake, which can be altered 
by competition with arginine at the BBB. The brain imports L-carnitine via one 
or more organic cation transporters (e.g., SLC22A5 and SLC22A4). In the mi-
tochondrial matrix, acyltransferases theoretically drive the transfer of glutaryl 
moieties from glutaryl-CoA to L-carnitine to liberate free coenzyme A (CoA) and 
form glutarylcarnitine, which can traverse multiple cellular barriers and be 
excreted. The quantitative importance of this ‘detoxification’ reaction in vivo is 
uncertain. The BBB is relatively impermeable to 5‑carbon dicarboxylic acids 
and therefore the brain accumulates glutarate and 3-hydroxyglutarate to con-
centrations two to three orders of magnitude higher than those measured in 
plasma. These compounds exhibit a range of neurotoxic actions in cell culture 
and Gcdh−/− mice. 
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other amino acids. Lys−Arg+ metabolic formula powder was available 
in two forms containing either 12% (Glutarade Junior) or 30% (Glu-
tarade Essential) amino acids per dry powder weight, intended for use 
in younger versus older children, respectively. Both formulations had 
an energy content of 4 kcal per gram of dry powder. 
Infants in Cohort I ingested 70–90 mg/kg•day of lysine, which is 
close to that of nursing babies (107 mg/kg•day), matches recommended 
safe intake (62–89 mg/kg•day), and exceeds the factorial estimate for 
normal growth (45–50 mg/kg•day) [16,17]. Blending intact protein and 
Lys−Arg+ formula protein in a 1:1 ratio decreases the proportion of 
ingested lysine to arginine approximately four-fold, from 2.3–3.0 to 
0.54–0.73 mg:mg (Table S2). L-arginine was not added to the diet as a 
separate supplement. L-carnitine (100 mg/mL) was dosed consistently 
at 100 mg/kg•day, rounded up to the nearest 0.5 mL increment. 
After age two years, we recommended children with GA1 continue 
an enteral L-carnitine supplement (~1000 mg daily), observe a modest 
natural protein restriction (1.0–1.3 g/kg•day), and supplement their 
diet with lysine-free, arginine-enriched amino acids from Glutarade 
Essential (30% Lys−Arg+ amino acids per dry powder weight). 
However, the large majority of parents ultimately chose to disregard 
these recommendations, such that most individuals with GA1 had a 
fully unrestricted diet by seven years of age (see below). 
2.2.2. Feeding strategy 
Once daily, formula was prepared to a concentration and volume 
appropriate for age using components measured in milliliters, ounces, 
or grams (on a digital kitchen scale) (Table 3). In contrast to alternating 
nutritional sources throughout the day, we combined all components, 
including L-carnitine, into the same 24-h mixture. To allow for normal 
variation in both energy requirement and feeding behavior, infants 
were allowed to feed ad libitum according to their natural schedule 
within ± 20% of the prescribed daily volume. When human milk was 
used as the source of intact protein, it was expressed, precisely mea-
sured, and added along with Lys−Arg+ powder and L-carnitine into the 
daily formula. Each child began a flexible transition to table foods be-
tween 6 and 14 months of age based on developmental cues. Table food 
was prescribed as average daily protein in grams (rather than milli-
grams of lysine), allowing for ± 15–25% variation day to day. We 
subtracted intact table food protein from the quantity in formula to 
maintain a total intact protein allocation of ~1 g/kg•day (Table 3). No 
children in Cohort I were fed via nasogastric or gastrostomy tube. 
2.2.3. Emergency intravenous infusion therapy 
We considered inpatient IV infusion therapy for any child who ex-
hibited signs of an infectious illness or other serious medical condition. 
The decision to hospitalize was based on the perceived threat of en-
cephalopathic crisis as influenced by age, feeding behavior, and the 
severity and duration of illness. Based on historical observations, we 
considered children to be at particularly high risk for brain injury if 
they were  <  24 months of age and had anorexia, gastroenteritis, or 
signs of any infectious illness lasting more than 1–2 days, even in the 
absence of fever. The standard inpatient protocol consisted of 10% 
dextrose in normal saline infused at 1.5-times the maintenance rate 
(glucose infusion 10–12 mg/kg•min), IV L-carnitine (100 mg/kg•dose) 
every 6–8 h (300–400 mg/kg•day), and supportive antiemetic, anti-
pyretic, and antimicrobial agents as indicated (Table 2). Because dex-
trose, saline, and L-carnitine were consistently administered in parallel, 
we could not isolate the independent therapeutic role of each, and 
therefore refer to this combination simply as emergency IV infusion 
therapy. 
2.2.4. Biochemical monitoring 
Children on protocol were seen monthly in clinic during the first 
year of life and every two months during the second year of life 
(Table 2). Plasma amino acids were collected at each visit and the 
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adjusted to achieve a plasma lysine concentration of 60–100 μmol/L 
and a plasma Lys/Arg ratio ≤ 1.0 mol:mol. Following the initial di-
agnosis of GA1, we did not use blood C5DC or urine organic acid levels 
to guide management. Plasma acylcarnitines were monitored only for 
research documentation or suspected/known dietary non-adherence. 
To evaluate the long-term safety of Lys−Arg+ metabolic formula, we 
collected general laboratory measures in each subject at a median age 
of 2.5 (range 0.4–11.0) years. 
2.2.5. Data collection 
During routine outpatient visits, we collected data about growth, 
psychomotor development, metabolic formula intake, and plasma 
amino acid concentrations. For the purpose of this investigation, we 
restrict detailed diet and amino acid information to the first two years 
of life, which roughly defines the window of neurologic vulnerability 
observed in Cohorts I–III and allows for reliable dietary accounting. The 
timing of motor milestone acquisition was compared to that of healthy 
siblings without GA1. A subgroup of 10 children from Cohort I (median 
7.0, range 5–12 years) and their age-matched (p = .086) unaffected 
siblings (median 8.9, range 6–17 years) completed Stanford-Binet 
Intelligence Scales, 5th Edition (SB-5), comprised of eight subscales: 
full-scale intelligence quotient (FSIQ), verbal IQ, non-verbal IQ, 
working memory, and knowledge, as well as visual-spatial, quantita-
tive, and fluid reasoning [18]. 
2.3. Estimation of Cerebral Amino Acid Influx 
For patients in Cohort I treated with Lys−Arg+ metabolic formula, 
we designed a custom Excel spreadsheet (Microsoft Corporation) to 
estimate cerebral uptake of circulating amino acids during the first two 
years of life [16]. Briefly, a group of three cationic amino acids (lysine, 
arginine, ornithine) compete for entry into the brain via a common 
facilitative transporter (SLC7A1; a.k.a. CAT1, y+) [19,20] which is 
saturated under physiological conditions, such that cerebral influx of 
each SLC7A1 substrate is influenced by ambient plasma concentrations 
of its competitors. Competition is expressed by an apparent Km, called 




K K 1 (C /K )napp m 1– n i i (1) 
where Km is the classical Michaelis-Menten affinity constant for the 
single amino acid of interest, Ci is the plasma concentration (μmol/L) 
for each of n competitors, and Ki is the classical affinity constant of that 
competitor (μmol/L). For a given plasma amino acid profile, Kapp values 
were determined for each SLC7A1 substrate using empirically-derived 
Michaelis-Menten constants [21]. The Kapp value was then used to es-
timate the brain influx (nmol per minute per gram of brain tissue) of 
each amino acid in the competing group, according to the equation: 
= +Influx (V )(C)/(K C)max app (2) 
where Vmax and C are the maximal transport velocity (nmol/min•g) and 
plasma concentration (μmol/L), respectively, of each amino acid [22]. 
Estimated brain influx values were compared to those calculated from a 
pediatric control population (N = 52) and depicted as standard scores 
(i.e., z-scores), where z = [(study subject value – control mean)/control 
standard deviation]. All cerebral uptake values represent calculated 
heuristics and should not be interpreted as direct measurements of 
amino acid flux. An analogous method was used to estimate brain up-
take of zwitterionic amino acids (glutamine, histidine, isoleucine, leu-
cine, methionine, phenylalanine, threonine, tryptophan, tyrosine, and 
valine) that compete for entry into the brain via the SLC7A5 transporter 
[21]. 
2.4. Statistics 
Statistical calculations were performed using Prism 8 software 
(https://www.graphpad.com). Kaplan-Meier analyses were applied to 
outcomes of striatal degeneration, death, and time to motor milestone 
acquisition. The two-sided Fisher's exact test was used to calculate re-
lative risk of brain injury in Cohorts II and III as compared to Cohort I. 
Normal reference plasma amino acid concentrations were derived from 
52 non-fasted healthy children without disorders of amino or organic 
acid metabolism and converted to z-scores for graphical representation 
[16]. Developmental trajectories of GA1 patients were compared with 
those of healthy siblings using Mann-Whitney and logrank Mantel-Cox 
tests. The two-tailed Student's t-test was used to compare SB-5 scales 
between GA1 subjects and their age-matched sibling controls. Paired 
vital signs before and 18–36 h into IV infusion therapy were compared 
using the Wilcoxon signed-rank test. To investigate differences among 
three or more groups, we used one-way analysis of variance (ANOVA) 
followed by the Tukey post-test for pairwise comparisons. Most con-
tinuous data sets (e.g. plasma amino acid concentrations and con-
centration ratios) were not normally distributed, and thus their central 
tendency is reported as the median and 25th to 75th interquartile range 
(IQR) except where otherwise noted. 
3. Results 
3.1. Cohort I (DOB 2006–2019): prospective treatment and monitoring 
3.1.1. Diagnosis 
Forty-one (68%) children in Cohort I were homozygous for GCDH 
c.1262C  >  T (p.Ala421Val). For 17 of them, this risk for GA1 was 
Table 3 
Sample 24-h Diets for Infants and Children in Cohort Ia        
Age, months 2 6 12 15 20 
Approximate Weight, kg 4.5 8.0 10.0 10.5 11.5  
Dietary variables 
Intact protein, g/kg•day 1.2 1.1 1.0 1.0 1.0 
Protein equivalent from Lys−Arg+ metabolic 
formula, g/kg•day 
1.2 1.1 1.0 1.0 1.0 
L-carnitine, mg/kg•day 100 100 100 100 100 
Total calories, kcal/kg•dayb 110 95 75 35 15 
Total formula volume, mL/kg•dayc 140 120 95 45 20  
Sample dietary components 
Human milk, ouncesd 16 – – – – 
Commercial milk-based formula powder, 
grams 
– 90 85 – – 
Cow or soy milk, ouncesd – – – 6 – 
Lys−Arg+ (12% AA content) formula 
powder, gramse 
45 75 85 45 – 
Lys−Arg+ (30% AA content) formula 
powder, gramse 
– – – 20 40 
Intact protein from table food, grams – – 1–2 3–5 10–13 
L-carnitine (100 mg/mL), mL 4.5 8.0 10.0 11.0 11.5 
Add potable water to make total 24-h 
volume, ounces 
21 32 32 16 8 
Formula concentration, kcal/oz 24 24 23 23 20 
a Diets listed above are intended to serve as examples only; individual diets 
and formula components will vary based on patient/family preference and 
natural feeding behaviors. 
b Total calories include those from human milk, cow/soy milk, or Lys- 
Arg + metabolic formula, but not those from table food. 
c Total volume includes human milk, cow/soy milk, or Lys-Arg + metabolic 
formula, but not other fluid sources (e.g. juice, almond milk, rice milk, etc.), 
which we did not attempt to quantify. 
d Composition per ounce: Human milk, 20 kcal, 0.33 g protein; Cow milk, 
20 kcal, 1 g protein; Soy milk, 20 kcal, 1 g protein. 
e There are two formulations of Lys−Arg+ formula powder which contain 
either 12% (Glutarade Junior) or 30% (Glutarade Essential) amino acids per dry 
powder weight, intended for younger versus older children, respectively. Both 
formulations have an energy content of 4 kcal per gram of dry powder.  
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known prenatally and molecular testing of umbilical cord blood in our 
CLIA-certified molecular laboratory yielded a definitive diagnosis at a 
median of one (range 0–4) postnatal day(s). Among 43 remaining pa-
tients in Cohort I, dried filter paper blood spots were collected at a 
median of 2 (range 0–5) postnatal days and results were reported 
through state NBS at a later median age of 8 (range 5–14) days 
(p  <  .0001). The median diagnostic filter paper C5DC concentration 
was 1.15 (IQR 0.88–1.78) μmol/L and the minimum was 0.42 μmol/L 
(normal reference value < 0.27 μmol/L). In Pennsylvania, NBS in-
cluded reflex tier two testing for the GCDH c.1262C  >  T variant. We 
encountered no false negative or false positive screening results at our 
center between 1994 and present. 
3.1.2. Dietary therapy 
For each child in Cohort I, we analyzed an average of 18 diets 
prescribed between birth and two years of life (1061 dietary formula-
tions in total). Calories represented in milk sources and medical food 
closely matched estimated energy expenditure until ~12 months of age, 
after which unmeasured calories from table foods increased (Fig. 2a). 
We routinely prescribed equal quantities of intact and modified protein 
but infants tolerated higher proportional intact protein (1.1–1.4 g/ 
kg•day) during the first six months of rapid growth (Fig. 2b). After age 
two months, the most common source of intact protein shifted from 
breastmilk to commercial milk-based infant formula, and during the 
second year of life we introduced natural milk sources along with an 
increasing quantity and variety of table foods (Table 3, Fig. 2c). As 
children transitioned to natural foods, 42% switched to a Lys−Arg+ 
medical formula containing 30% (Glutarade Essential) as compared to 
12% (Glutarade Junior) amino acids per dry powder weight, which 
decreased their prescribed formula volume by 50–75% (Table 3). The L- 
carnitine supplement for each child in Cohort I was consistently 
~100 mg/kg•day during the first two years of life and at no time 
was < 50 mg/kg•day (Fig. 2d). 
3.1.3. Outpatient biochemical monitoring, birth to two years 
We collected and analyzed a total of 1054 plasma amino acid 
samples in the outpatient setting from children in Cohort I; 855 of these 
were obtained during the first two years of life under conditions of strict 
dietary adherence (average of 14 per subject and one per visit). Here, 
we define a ‘strict’ diet as one in which intakes of both intact and lysine- 
free protein were reliably known and the prescribed and ingested vo-
lume of Lys−Arg+ metabolic formula closely aligned. The ‘relaxed’ diet 
applies to older children on a recommended but unquantified (typically 
higher) range of intact protein, whose intake of metabolic formula often 
fell short of the recommended volume. 
A strict Lys−Arg+ diet was associated with median plasma lysine 
and arginine concentrations of 80 (IQR 60–100) μmol/L and 98 (IQR 
80–115) μmol/L, respectively (Fig. 3a), and a median plasma Lys/Arg 
Fig. 2. Cohort I: Dietary variables from Birth to 24 Months. (A) For the first 12 months of life, average prescribed calories from formula (red circles, ± 1SD) closely 
matched estimated energy requirement (EER) as determined by the doubly-labeled water method (DLW; https://www.nap.edu/), shown as a blue dotted line. 
Unmeasured calories from table foods increase during the second year of life. (B) Intact protein (gray diamonds) and lysine-free, arginine-enriched amino acids from 
metabolic formula (Lys−Arg+; red circles) were prescribed in approximately equal quantities throughout the first two years of life. (C) After ~8 months of age, the 
proportion of intact protein from table food (gray) as compared to milk sources (red) increased. (D) The average enteral L-carnitine supplement was ~100 mg/kg•day 
(red line) and at no time decreased to < 50 mg/kg•day (gray circles). 
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ratio of 0.8 (IQR 0.6–1.1) mol:mol (Table 4, Fig. 3b). Children ingesting 
Lys−Arg+ formula had normal circulating concentrations of all SLC7A1 
and SLC7A5 amino acid substrates (z scores +2 to −2) with the no-
table exception of lysine, which was 38% below the normal reference 
median and had the lowest reference-adjusted plasma concentration. 
Based on plasma concentrations of lysine, arginine, and ornithine in 
children on strict dietary therapy, we estimated median cerebral lysine 
uptake to be approximately 40% lower than values derived from either 
a control population or older GA1 subjects on unrestricted diet (Table 4,  
Fig. 3c). Calculated brain uptake values for all other SLC7A1 and 
SLC7A5 substrates, including tryptophan, were within the normal re-
ference range (Fig. 3d). 
Serum folate concentration exceeded the limit of quantitation 
(> 20 ng/mL) in children taking Lys−Arg+ metabolic formula; those 
on supplemental L-carnitine had elevated total and free plasma carni-
tine levels (p  <  .0001). Other laboratory indices of nutritional suffi-
ciency and general health were within normal reference intervals 
(Table S3). Plasma tryptophan values were within the normal range 
(Table 4) and no child in Cohort I developed signs of tryptophan or 
niacin deficiency (i.e. pellagra) [23]. 
3.1.4. Dietary adherence 
All Cohort I subjects remained on a strict diet using Lys−Arg+ 
metabolic formula until two years of age. Dietary adherence decreased 
steadily thereafter, so that the probability of a child remaining on 
Lys−Arg+ metabolic formula after age seven years was only 12% 
(Fig. 4a). Cessation of diet was associated with a higher median plasma 
lysine concentration and Lys/Arg ratio (Table 4, Fig. 3b). Similarly, 
only 32% of GA1 subjects remained on an L-carnitine supplement after 
age six years. Plasma free and total carnitine decreased markedly as a 
consequence but we observed no overt clinical signs of carnitine defi-
ciency (Fig. 4b). 
3.1.5. Hospitalizations 
There were 153 recorded hospitalizations for children in Cohort I. 
During the first two years of life, each child was hospitalized a median 
Fig. 3. Cohort I: Outpatient Biochemical Monitoring (n = 1054 amino acid samples). (A) The mixture of intact protein with Lys−Arg+ metabolic formula achieved a 
dietary lysine to arginine ratio of ~0.5 mg:mg, which maintained plasma lysine (red circles, ± 1SD) and arginine (gray diamonds) at nearly equal concentrations. (B) 
The average ratio of lysine to arginine in plasma (Lys/Arg) was ≤1.0 on strict diet (red circles, mean, ± 1SD) but increased as adherence to both intact protein 
recommendations and metabolic formula intake became more relaxed after age two years (blue diamonds). Most GA1 subjects older than 7 years (gray triangles) no 
longer restricted their natural protein intake or used Lys−Arg+ metabolic formula and their plasma Lys/Arg ratios increased to the normal control range (gray 
shading, median and IQR; ****p  <  .0001). (C) Plasma lysine, arginine, and ornithine concentrations were used to estimate cerebral lysine influx in relation to 
dietary exposure in four groups: pre-treated newborns (dark gray squares), young children on a strict diet using Lys−Arg+ metabolic formula (red circles), children 
on a relaxed intake of metabolic formula and natural protein (blued diamonds), and older children on an completely unrestricted natural diet (open gray triangles). 
The gray shaded area represents estimated cerebral lysine uptake (median and IQR) calculated from plasma amino acid profiles of 52 healthy children without GA1. 
Age on the abscissa is depicted as a log10 scale with a vertical dashed line at age two years. (D) For children ≤2 years of age on a strict Lys−Arg+ diet, lysine (red 
circles) and arginine (blue circles) had the lowest and highest adjusted cerebral uptake values, respectively, depicted here as z-scores (gray shading represents the 
normal z-score range of −2 to +2). Calculated brain uptake values for all other SLC7A1 and SLC7A5 substrates (gray circles), including tryptophan, were within the 
normal reference range. 
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of three (range 0–14) times and 85% of children were hospitalized at 
least once for emergency IV therapy. The median age of hospitalization 
was 12.6 months for the main indications of gastroenteritis (44%), re-
spiratory tract infection (32%), fever without an identified source 
(16%), and acute otitis media (5%). Each hospitalization lasted a 
median of two (1–8) days. 
For children in Cohort I, Table 5 lists vital signs and select labora-
tory values recorded at the time of admission and again an average of 
24 (18–36) hours into the course of emergency IV therapy. Two-thirds 
of patients admitted to the hospital before age two years had objective 
signs of inflammation indicated by elevated body temperature 
(> 38 °C, 100.4 °F) and/or a serum C-reactive protein concentra-
tion  >  8.0 mg/dL. These two variables were modestly correlated 
(rs = 0.42, p  <  .0001). Average body temperature did not change 
during the first 18–36 h of hospitalization (p = .620). Heart rate and 
blood pressure were generally within the normal range at the time of 
admission and decreased 2.4–7.0% during IV therapy (p  <  .0001). 
Laboratory studies collected at the time of admission did not show 
metabolic acidosis or hypoglycemia; this was true even in two patients 
who presented with acute striatal necrosis. The mean presenting serum 
total carbon dioxide and anion gap were 22  ±  3 (range 13–29) mmol/ 
L and 11  ±  3 (range 5–21) mmol/L, respectively, and only two chil-
dren (1.3%) presented with a serum total carbon dioxide concentra-
tion  <  16 mmol/L. The average presenting serum glucose con-
centration was 95  ±  22 (range 47–202) mg/dL; only four values 
(2.6%) were  <  60 mg/dL and these were not associated with signs of 
neuroglycopenia or metabolic stroke. For more than 90% of hospitali-
zations, blood was collected only at the time of admission. For the few 
subjects who had at least one repeat set of laboratory studies (n = 14), 
average serum glucose increased in response to IV dextrose, but this 
result was not significant (p = .143) due to broad variation (−17% to 
+174%) among a small number of samples. No child developed hy-
perglycemia sufficient to warrant insulin therapy. 
There were no serious adverse events associated with dextrose 
Table 4 
Plasma Amino Acids and Estimated Cerebral Lysine Influx Relative to Dietary Exposurea.          
Age Range (years) Plasma concentration, μmol/L Plasma Lys/Arg Ratio, 
mol:mol 
Cerebral Lys Influx, nmol/ 
min gc 
Lysine Arginine Tryptophanb  
Normal reference control (n = 52)  130 (97–180) 73 (42–94) 52 (35–62) 2.0 (1.4–2.7) 8.6 (7.0–9.6) 
Strict Lys−Arg+ Metabolic Formula Diet  
(n = 855)d 
Birth–2.0 80 (60–100) 98 (80–115) 38 (31−101) 0.8 (0.6–1.1) 5.4 (4.3–6.3) 
Relaxed Lys−Arg+ Metabolic Formula Diet  
(n = 150)d  
> 2.0–13.8 97 (73–129) 82 (62–102) 36 (30–44) 1.3 (0.9–1.9) 6.8 (5.3–8.2) 
Unrestricted Natural Diet (n = 49) 9.3–30.8 167 (129–213) 74 (41–91) na 2.3 (1.6–4.2) 9.7 (8.7–10.9) 
ANOVA P value   < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001 
Pairwise comparisons (Tukey)       
Control vs. Strict Lys−Arg+   < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001 
Control vs. Relaxed Lys−Arg+   < 0.0001 0.0651  < 0.0001  < 0.0001  < 0.0001 
Control vs. Unrestricted   < 0.0001 0.9993 na 0.0448 0.0083 
Strict Lys−Arg+ vs. Relaxed Lys−Arg+   < 0.0001 0.0006 0.8386 0.2626  < 0.0001 
Strict Lys−Arg+ vs. Unrestricted   < 0.0001  < 0.0001 na  < 0.0001  < 0.0001 
Relaxed Lys−Arg+ vs. Unrestricted   < 0.0001 0.1065 na 0.0038  < 0.0001 
Abbreviations: IQR, interquartile (25th–75th) range; na, not applicable due to insufficient plasma tryptophan data. 
a All descriptive statistics are expressed as median (IQR), where IQR is the 25%–75% interquartile range. 
b Most amino acid profiles from the “Unrestricted Natural Diet” group were acquired before the CSC laboratory accurately quantified tryptophan in plasma. 
c Cerebral lysine (Lys) influx is not a measured value; rather, it is calculated using empirically derived Michaelis-Menten constants for lysine, arginine, and 
ornithine. 
d We define a ‘strict’ diet as one in which intact protein is precisely quantified; the ‘relaxed’ diet applies to older children on a recommended but unquantified 
range of intact protein.  
Fig. 4. Cohort I: Dietary Adherence. (A) All Cohort I subjects remained on Lys−Arg+ metabolic formula during the first two years of life (gray shaded area). 
Thereafter, the majority of families stopped dietary therapy of their own accord. By age seven years, the probability that a child from Cohort I remained on metabolic 
formula (red solid line) or enteral L-carnitine (gray dashed line) decreased to 12% and 32%, respectively. (B) Relative to healthy non-GA1 controls (light gray bars, 
mean  ±  1SD), GA1 subjects on an L-carnitine supplement (red bars) had higher total and free carnitine concentrations in plasma. Cessation of L-carnitine therapy 
(dark gray bars) was associated with five-fold decreases of plasma total and free carnitine but no overt clinical signs of carnitine deficiency (****p  <  .0001). 
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infusions of 9–12 mg/kg•min or L-carnitine doses ≤400 mg/kg•day, 
which were administered exclusively by peripheral (as opposed to 
central) vein. No child developed motor regression while receiving 
emergency IV therapy. 
3.2. Clinical outcomes in cohorts I-III 
3.2.1. Psychomotor outcomes 
The incidence of striatal degeneration in Cohorts I, II, and III was 
7%, 47%, and 90%, respectively (p  <  .0001) (Fig. 5a). Newborn 
screening decreased the relative risk of striatal degeneration 7-fold 
(p  <  .0001; 95%CI 3- to 19-fold, p  <  .0001) and, when coupled to 
the use of Lys−Arg+ metabolic formula, 14-fold (95%CI 6- to 35-fold, 
p  <  .0001) (Table 1). No neurologic injuries occurred after 19 months 
of age. 
The proportion of striatal lesions that presented as acute en-
cephalopathic crisis versus insidious motor delay was 84% before the 
advent of NBS (Cohort III) and 50% in the modern NBS era (Cohort I). 
Children with insidious motor delay tended to have better functional 
outcomes as compared to those who presented with acute motor re-
gression. In Cohort I, two children were rendered mute, non-ambula-
tory, and fully disabled after suffering acute striatal necrosis; two ad-
ditional children from this cohort had infantile-onset hypotonia and 
dystonia but no witnessed encephalopathic crisis. They learned to crawl 
(12.5 and 13 months) and walk independently (24 months) and now 
enjoy a high degree of self-efficacy. 
All 91 subjects with GA1 who were spared neurologic injury are 
alive and well at a mean follow up of 9.6  ±  8.3 (range 0.2–43.4) years. 
Uninjured children from Cohort I (n = 56) who took Lys−Arg+ me-
tabolic formula grew normally during the first two years of life (Fig. 6). 
They achieved independent sitting (5–9 months) and crawling 
(8–11 months) as expected relative to their unaffected siblings (Fig. 7a- 
d), but walked about two months later, at a median of 14 as compared 
to 12 months (p = .045). First articulate words were similarly delayed 
about two months (p = .036). Ten subjects from Cohort I who were old 
enough for cognitive testing (5–12 years) scored similar to their age- 
matched control siblings on FSIQ and SB-5 subscales (Fig. 7e). 
3.2.2. Mortality and comorbidity 
Across cohorts, a total of 77 patients suffered brain injury (Cohort I, 
n = 4; Cohort II, n = 27; Cohort III, n = 46). Post-mortem and neu-
roimaging studies consistently showed bilateral neuronal loss and 
gliosis of the lentiform nuclei in a dorsolateral to ventromedial gradient 
ranging from mild to severe (Fig. 8a). Eighteen patients with striatal 
lesions were lost to clinical follow up. Of the 59 remaining, 24% 
(n = 14) died from complications of dystonia at a median age of 14.5 
(range 2.5–39.1) years (Fig. 5b). Medical and surgical comorbidities 
were common among survivors; most became wheelchair-dependent 
Table 5 
Cohort I: Measurements at the Time of Hospital Admission and 18–36 Hours Into IV Infusion Therapy (n = 153 Hospitalizations).        
Hospital admission Infusion therapy 18–36 Hours Relative change Wilcoxon P 
Mean  ±  SD (Range) Mean  ±  SD (Range)  
Vital signs 
Body temperature, Co 37.4  ±  0.8 (34.9–40.6) 37.5  ±  0.9 (36.1–39.9) 0.10% 0.620 
Heart Rate, bpm 134  ±  16 (100–188) 130  ±  13 (86–170) –2.4% 0.018 
Systolic blood pressure, mmHg 110  ±  13 (81–145) 104  ±  11 (80–134) −4.6%  < 0.0001 
Diastolic blood pressure, mmHg 65  ±  12 (41–90) 58  ±  9 (42–88) −7.0%  < 0.0001  
Serum biomarkers 
Glucose, mg/dL 95  ±  22 (47–202) 110  ±  28 (79–182) 28% 0.143 
Bicarbonate, mmol/L 22  ±  3 (13–29) na   
Anion Gap, mmol/L 11  ±  3 (5–21) na   
Blood Urea Nitrogen, mg/dL 12  ±  4 (5–30) na   
Creatinine (mg/dL) 0.27  ±  0.06 (0.20–0.40) na   
Alanine Aminotransferase (U/L) 27  ±  14 (11–89) na   
C-reactive Protein (mg/L) 18.9  ±  7.7 (< 0.02–100) na   
Abbreviations: C, Celsius; na, not available; SD, standard deviation.  
Fig. 5. All Cohorts: Clinical Outcomes. (A) The incidence of striatal degeneration in Cohorts I (blue solid line), II (gray dotted line), and III (red dashed line) was 7%, 
47%, and 90%, respectively (p  <  .0001). In 168 patients managed over a span of three decades, no brain injuries were observed after age 19 months (gray shaded 
area). Note divided abscissa. (B) Striatal lesions were a risk factor for untimely death (red dashed line; median survival 39 years, p = .0024). All 91 patients who 
escaped neurologic injury are alive and functionally independent (gray solid line). 
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for mobility, required gastrostomy feeding, and were rendered dys-
arthric or mute. Intellect was typically preserved, but dystonia often 
posed an insurmountable barrier to the use of assistive communication 
devices. 
3.2.3. Medical and surgical management of dystonia 
For GA1 patients with neurologic injury, diazepam was the main-
stay of medical management, acting as both a central muscle relaxant 
and anxiolytic to reduce dystonia. Diazepam was typically administered 
three of four times daily at doses titrated to balance therapeutic benefit 
against side effects of sedation and sialorrhea. Tolerance was common 
with this agent; after years of exposure, patients could require 1.5 mg/ 
kg•day or more to sustain efficacy. Enteral baclofen was rarely used as 
adjunctive therapy. Levodopa and trihexyphenidyl, sometimes used to 
treat movement disorders in children [24], were ineffective against 
GA1-associated dystonia. Four patients gained moderate relief from 
continuous intrathecal (n = 2) or intraventricular (n = 2) baclofen 
[25,26]. One adult patient who underwent internal pallidal deep brain 
stimulation reported subjective relief of musculoskeletal pain but ex-
hibited no objective improvements in dystonia rating scales or motor 
function. 
There were 35 orthopedic procedures performed among 16 (21%) 
individuals (1–5 operations per patient) to manage musculoskeletal 
complications such as scoliosis (n = 11; Fig. 8b) and hip dislocation/ 
subluxation (13 hips in 8 patients). The average age at first operation 
was 13.8 (range 6–25) years (Figs. 8c) and the most common 
procedures were posterior spinal fusion and proximal femoral varus 
derotation osteotomy and/or pelvic osteotomy (Fig. 8d). During the 
postoperative period, pain and anxiety often exacerbated dystonia in a 
self-reinforcing cycle, sometimes escalating to life-threatening status 
dystonicus. 
4. Discussion 
4.1. Pathophysiology and prevention of striatal degeneration 
The GCDH-deficient brain accumulates glutaryl-CoA, GA, and 3HGA 
proportional to its rate of lysine uptake [27,28], which is highest during 
embryonic life and early infancy [29,30]. Studies in cell culture and 
transgenic Gcdh−/− mice reveal the potential for these compounds to 
activate excitotoxic cascades, amplify oxidative stress, inhibit re-
spiratory complexes, depress sodium‑potassium ATPase activity, and 
disrupt the maturation and function of astrocytes [31–39]. One or more 
of these mechanisms might precipitate striatal degeneration, but none 
fully explain its temporal and histological selectivity. The maturation of 
medium spiny neurons must also play a role, rendering them uniquely 
vulnerable to histotoxins during a circumscribed phase of development 
[40,41]. 
Neuroimaging studies indicate how this biochemical state might 
affect the developing brain. Asymptomatic infants with GA1 have re-
duced fluorodeoxyglucose uptake in the lentiform nuclei, reduced cer-
ebral blood flow (CBF), and signs of cerebrovascular congestion [9,42] 
that coincide with normal developmental surges of synaptogenesis, 
excitatory neurotransmission, substrate utilization, and perfusion 
[43–45]. As this normal developmental sequence unfolds, medium 
spiny neurons in the striatum––with their unique constellation of 
channels, receptors, and enzymes [40]––potentially experience a mis-
match between energy supply and demand during a time when they are 
unusually sensitive to excitotoxic and oxidative forms of injury 
[46–48]. 
Based on the foregoing model, protecting the striatum from GCDH 
deficiency is predicated on minimizing its exposure to neurotoxins 
during a discrete phase of development [41]. In principle, this is ac-
complished by manipulating dietary amino acid content to reduce 
cerebral lysine influx while administering L-carnitine to clear glutaryl- 
CoA from brain cell mitochondria (Fig. 1, [16,27,49–51]. The provision 
of ‘emergency’ therapy in the form of IV dextrose and saline is intended 
to stabilize energetically fragile brain tissue during intervals of phy-
siologic stress [41]. 
Beginning in 1989 [52,53], NBS allowed us to detect pre-sympto-
matic Amish babies with GA1 and decrease their risk of neurologic 
injury from 90% (Cohort III) to 47% (Cohort II), representing a seven- 
fold reduction of relative risk. The use of Lys−Arg+ metabolic formula 
in Cohort I further reduced the incidence of striatal degeneration to just 
7% (14-fold reduction of relative risk) [16]. Our experience aligns 
closely with that of Boy et al., who found that NBS for GA1 in Germany 
reduced the incidence of neurologic injury from > 90% to 36% and, 
when coupled to lysine-restricted diet, to 7% [54]. Taken together, 
these data show that: (1) the neuroprotective effects of emergency IV 
therapy and Lys−Arg+ metabolic formula are additive; (2) metabolic 
formulas devoid of lysine might be to some degree interchangeable; (3) 
similar outcomes can be expected in cohorts that differ with regard to 
the distribution of pathogenic GCDH genotypes; and 4) the same basic 
elements of therapy can be deployed in various settings to comparable 
effect. 
4.2. Elements of effective therapy 
Newborn screening with tandem mass spectrometry (TMS) detects 
GA1 with a sensitivity and specificity of at least 93% and 99%, re-
spectively [15,55,56]. In certain populations like the Amish, targeted 
allele detection enables molecular diagnosis within hours of life [12] 
Fig. 6. Cohort I: Growth from Birth to Two Years. Average weight (A), length 
(B), and head circumference (C) were normal during the first two years of life 
for children in Cohort I (red circles, mean  ±  1SD). Gray shaded areas represent 
World Health Organization reference intervals for females (3rd to 97th centile). 
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but this strategy does not appear to improve outcome over standard 
TMS-based methods with ~8-day turnaround. Pre-symptomatic diag-
nosis not only reduces the risk of neurologic impairment but also its 
potential severity. In the absence of NBS for GA1, ~85% of striatal 
lesions present as acute, pan-striatal cytotoxic edema that culminates in 
extensive neuronal loss, generalized dystonia, and profound functional 
impairment (Cohort III). In the post-screening era, ~50% of children 
with striatal degeneration present with insidious motor delay; the 
Fig. 7. Cohort I: Developmental and Cognitive Outcomes. Uninjured children from Cohort I (n = 56) who took Lys−Arg+ metabolic formula during the first two 
years of life (red solid lines) achieved independent sitting (A) and crawling (B) as expected relative to their unaffected siblings (gray dashed lines) but walked 
independently (C) and used their first articulate words (D) about two months later. Ten subjects from Cohort I (red circles, ± 1SD) who were old enough for cognitive 
testing (median 7.0, range 5–12 years) scored similar to their age-matched control siblings (median 8.9, range 6.0–17.1 years) on FSIQ and SB-5 subscales [verbal IQ 
(VIQ), non-verbal IQ (NVIQ), working memory (WM), and knowledge (K), as well as visual-spatial (VS), quantitative (QR) and fluid (FR)]. The horizontal dashed line 
represents absolute equivalence (i.e., 0% difference relative to an age-matched sibling). 
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associated brain lesions are typically confined to the dorsolateral pu-
tamen, visible months or years before a conspicuous movement dis-
order, and predictive of a better functional outcome [9,10]. 
Following the diagnosis of GA1 by NBS, use of a metabolic formula 
devoid of lysine and enriched with arginine establishes desired plasma 
amino acid concentrations ranges that can be maintained throughout 
the transition from formula to table foods. Because transport Km values 
for lysine (Km = 70 μmol/L) and arginine (Km = 56 μmol/L) at the 
blood-brain barrier are similar [21], they exhibit meaningful transport 
competition within concentration ranges induced by Lys−Arg+ meta-
bolic formula. Based on our calculations, dietary management with 
Lys−Arg+ formula could decrease the brain's toxin exposure by as 
much as 40% during its vulnerable phase of development, but this also 
has potential to interfere with normal brain growth [57–59]. Mindful of 
this risk, we monitor infants with GA1 every month. In general, those 
who adhere to a strict therapeutic diet during the first two years of life 
exhibit normal growth, achieve developmental milestones on time, and 
have normal cognitive function later in childhood. Other investigators 
report similar outcomes, supporting the overall safety of current GA1 
treatment guidelines [60–63]. 
Rigid insistence on many aspects of feeding may not be necessary to 
ensure good outcome, provided medical food is balanced appropriately 
with other dietary components and offered ad libitum. We ask parents 
to quantify all dietary ingredients but allow them to combine these once 
daily into a single mixture, which they offer in rhythm with each baby's 
natural appetite and feeding cues. Following the transition to table 
foods, metabolic control can be maintained while also allowing for 
some flexibility (e.g., ± 20%) in daily protein intake. Outpatient 
monitoring is streamlined around just three parameters––physical 
growth, psychomotor development, and the plasma Lys/Arg ratio. 
As long as diet conforms to accepted guidelines [63,64] and is ad-
justed for incremental weight gain, normal development can be 
achieved with minimal or no specialized biochemical testing. Indeed, 
several families from Cohort I lived in geographically remote, resource- 
limited households and were unable to adhere to the demanding clin-
ical monitoring schedule. In between a more limited number of out-
patient visits, parents collected accurate growth measurements at home 
and communicated these to our clinical team in a way that allowed 
their children to have timely dietary adjustments and excellent neuro-
logic outcomes. 
There remains some controversy about the appropriate duration of 
prescription dietary therapy. In our experience over three decades, no 
neurological crises occurred after age 19 months, but the true window 
of striatal vulnerability remains unknown. In one large international 
cross-sectional study (n = 279), 95% of all brain injuries occurred 
before age 24 months but one was reported at 70 months. This unusual 
case is often cited to support the recommendation for strict dietary 
management until age six years [63,64]. Mindful of the potential for 
long term complications, we advise that GA1 patients > 19 months 
remain on dietary therapy. Nevertheless, most choose to quit diet of 
Fig. 8. Morbidity. (A) An axial brain section from a deceased GA1 patient shows characteristic atrophy of the striatum in a dorsolateral to ventromedial gradient (left 
hemisphere, red shading). A normal age-matched brain is shown for comparison (right hemisphere, blue shading). (B) Striatal lesions typically cause severe, 
generalized dystonia. (C) The large majority of patients with dystonia require one or more orthopedic surgeries to address common musculoskeletal complications 
such as scoliosis and hip dislocation. (D) A radiograph of the left hip shows the femoral head (red shading) dislocated from the acetabulum (blue dotted line) in an 
adolescent with GA1. 
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their own accord (Fig. 4A). Although we observed no overt con-
sequences of dietary non-adherence through adolescence and early 
adulthood, we recognize this might lead to complications later in life 
(see below). 
4.3. Knowledge gaps 
Intravenous infusion of dextrose, saline, and L-carnitine during ill-
ness is a widely accepted treatment strategy for GA1 [52,63,64]. We 
know very little about how this intervention protects the brain, but it is 
empirically successful; throughout 153 hospitalizations we attended 
over three decades, no GA1 patient developed neurologic regression 
while on inpatient IV therapy. With regard to the efficacy of IV infu-
sions, timing matters. Emergency IV therapy need not and should not be 
delayed to accommodate transport to a tertiary academic center; the 
infusion protocol can be safely administered at almost any hospital with 
basic pediatric services. Over the years, we have successfully collabo-
rated with community hospitals throughout the United States to es-
tablish convenient, affordable, and timely access to emergency IV 
therapy for children with GA1. 
Pathophysiological concepts that inform IV therapy continue to 
evolve. Following its initial discovery, GA1 was viewed as an episodic 
intoxication syndrome in which systemic proteolysis generates circu-
lating neurotoxins that cross the blood-brain barrier to poison the brain 
[52,65]. According to this paradigm, infusion of dextrose and saline 
were intended to suppress generation of organic acids and clear them 
from the bloodstream [6]. We now know this reasoning to be incorrect 
for a number of reasons: (1) ambient plasma concentrations of GA and 
3HGA in patients are much lower than histotoxic concentrations in 
vitro [33,66,2]) acute metabolic acidosis is seldom observed during 
catabolic states [9, 3) under all conditions, plasma GA and 3HGA are 
orders of magnitude below concentrations measured in brain tissue 
[67,68]; and (4) 5‑carbon dicarboxylates do not readily cross the blood- 
brain barrier [3,4,69]. Finally, the most compelling evidence comes 
from experimental Gcdh−/− mice, which only develop central nervous 
system intoxication in response to excess dietary lysine [27,28]. 
Over the last 15 years, attention has shifted to the possibility that 
dextrose-containing saline infusions somehow stabilize metabolically 
vulnerable neurons, perhaps by improving their substrate supply 
[9,42]. This would require that IV therapy augment cerebral glucose 
delivery by increasing one or both of its determinants: plasma glucose 
concentration and CBF. Contrary to this idea, we found that infusing 
glucose in saline at 10–12 mg/kg•min does not reliably increase plasma 
glucose concentration, nor does it impact hemodynamics in a way that 
should alter CBF, as indicated by similar blood pressure measurements 
before and after the initiation of emergency IV therapy. 
Like emergency IV infusion, L-carnitine supplementation is a widely 
accepted practice that lacks a strong evidence base [63,64,70]. Beyond 
its obvious role in correcting systemic deficiency, treatment with L- 
carnitine is founded on the premise that it crosses the blood-brain 
barrier, gains access to the mitochondrial matrix of neurons, and drives 
an acyltransferase reaction with glutaryl-CoA [2,71]. The human brain 
imports L-carnitine via a number of sodium-coupled transporters (e.g., 
SLC22A5 and SLC22A4; https://www.proteinatlas.org/) and, based on 
Km values measured in rat brain slices (1920–2850 μmol/L) [72,73], a 
five-fold increase in plasma carnitine should increase its cerebral up-
take by a comparable degree. However, the activity of neuronal car-
nitine acyltransferases toward 5‑carbon dicarboxylate thioesters ap-
pears to be quite low [71,74] and the quantitative relevance of 
mitochondrial ‘detoxification’ in vivo thus remains unclear. 
4.4. Challenges and opportunities 
Prior to the advent of TMS-based NBS in the United States, most 
neurologic injuries from GA1 were catastrophic in nature. We now have 
neuroprotective therapy that is safe, simple, and highly effective 
[75–78] but only a minority of developed nations currently screen for 
GA1 [75]. Among 46 patients in Cohort III with striatal lesions, more 
than 85% were Gross Motor Function Classification System (GMFCS) 
level V, requiring a wheelchair for mobility and retaining limited or no 
ability to maintain a seated or standing posture, control limb move-
ments, speak, or swallow [79]. When using a disability weighting 
consistent with severe functional impairment [80] and accounting for 
the attendant increase in mortality, these data suggest that in the ab-
sence of a systematic newborn screening and treatment program, each 
child born with GA1 loses an average of 64 disability-adjusted life 
years. 
The economic impact of NBS for GA1 is also considerable. In de-
veloped nations, aggregate direct, indirect, and social costs of caring for 
an individual with GMFCS V level disability is between $46,000 and 
$64,000 per annum (corrected to 2016 U.S. dollars). Considering a 39- 
year median survival for disabled GA1 patients, this extrapolates to a 
lifetime cost of between US$1.8 and 2.5 million per brain-injured in-
dividual. Recognizing both the social and economic implications [64], 
the U.S. Health Resources and Service Administration includes GA1 as a 
recommended condition for universal newborn screening for all babies 
born in the United States and allied territories (https://www.hrsa.gov/ 
advisory-committees/heritable-disorders/rusp/index.html). 
Although important evidence gaps remain, current protocols pre-
vent more than 90% of brain injuries and are unlikely to face competing 
strategies in the near future. A rough power calculation shows why; to 
be proven superior, any novel intervention needs to be tested in parallel 
against a cohort of equal size managed according to the current stan-
dard of care [63,64]. A statistically meaningful difference between 93% 
and 97% efficacy would require at least 250 infants in each treatment 
group. Given the potentially grave neurologic consequences of such a 
randomization, it would pose a serious ethical challenge and most 
parents would be reluctant to participate. 
4.5. Treatment of GA1 beyond early childhood 
A strong confluence of evidence from multiple sources now supports 
the use of dietary therapy to prevent striatal degeneration from GCDH 
deficiency. In contrast, only scattered and conflicting data inform 
treatment of GA1 beyond early childhood. The natural age-related de-
cline in treatment adherence brings this problem into sharp focus 
(Fig. 4A). In patients aged 8 to 71 years, symptoms and signs attributed 
to GA1 have included headache, nausea, nystagmus, gaze palsy, hy-
perreflexia, syncope, vertigo, epilepsy, ataxia, tremor, dysmetria, dys-
arthria, memory impairment, incontinence, orofacial dyskinesia, con-
fusion, dementia, and peripheral neuropathy [81–86]. Unfortunately, 
none of these clinical phenomena are specific to GA1 and no combi-
nation of them has coalesced into a distinctive late onset neurological 
‘phenotype’ of GA1. In at least half of GA1 subjects without striatal le-
sions, magnetic resonance images (MRI) reveal abnormal signals in 
white matter tracts and deep extrastriatal nuclei [61,81,87]. These 
likely reflect areas of interstitial edema and vacuolization 
[9,28,67,68,88–91], but it is not known how such changes correspond 
to neurological function or if they change in response to dietary treat-
ment. 
A similar consideration applies to the potential for non-neurological 
complications of GA1. For example, reports from experimental animals 
and humans indicate that GA1 might confer susceptibility to both acute 
[92–94] and chronic forms of kidney disease [95]. In Cohort I, we 
observed no signs of renal insufficiency among patients ≤3 years of age 
(mean serum creatinine 0.27  ±  0.06, range 0.20–0.40 mg/dL; Table 5) 
and, over the last three decades, had no GA1 patient present with overt 
renal failure. However, chronic renal insufficiency could go undetected 
among subjects from Cohorts II and III, for whom we have limited 
longitudinal renal biomarker data. It is important to reiterate, however, 
that the presence of a disease process, renal or otherwise, does not 
assure its response to therapy. The nephropathy of methylmalonic 
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acidemia (MMA) provides an instructive example; there is no indication 
that progression of kidney disease in MMA is altered by dietary therapy 
[96]. 
The possibility of late-onset disease complications must be balanced 
against the fact that individuals with GA1 can remain healthy well into 
adulthood after living decades with no specific therapy. Among 91 in-
dividuals we studied without striatal lesions, 59% ranging from 2.6 to 
43.6 years of age are off prescription medical foods and 52% stopped L- 
carnitine. Fourteen of them are > 17 years, have been off protein re-
striction and dietary supplements since early childhood, and report no 
clinically significant neurological problems or health concerns. Similar 
stories emerge from false positive NBS results that reveal GCDH defi-
ciency in otherwise healthy mothers [56,83,97,98]. 
The foregoing discussion should not be misinterpreted as a formal 
recommendation to stop dietary therapy for GA1 patients older than 
two years. Rather, we intend only to draw attention to a problem in 
need of more evidence. To this end, future clinical research should 
target two related but distinct questions: (1) Is it possible to more 
sharply define ‘non-striatal’ complications of GCDH deficiency after age 
two years, and consolidate these into something like a canonical late- 
onset GA1 phenotype that they can be reliably anticipated, measured, 
and tracked in a clinical setting?; and (2) If such a phenotype becomes 
established, can its natural course be altered by standard dietary 
therapies (e.g., lysine-restriction and/or enteral L-carnitine)? Separating 
these ideas is critically important, because the mere existence of a ra-
tional therapy does not guarantee its effectiveness [59]. 
Over the long term, patients' willingness to adhere to dietary 
therapy should improve if it can be linked to meaningful outcomes. In 
the absence of such associations, however, we recognize the potential 
for prolonged but unnecessary therapy to foster stigmatization, mala-
daptive relationships, and mental distress––a phenomenon termed the 
‘vulnerable child syndrome’, which can have serious long-term psy-
chological consequences [99]. Balancing the potential risks and benefits 
of treatment for GA1 beyond early childhood therefore represents an 
ongoing conundrum open to new research, and marks a pressing chal-
lenge for clinical investigators. 
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